Molecular Diagnostics Europe Day 2 #MDxE16 https://t.co/oFCfZcgdQ1
4:12am April 6th 2016 via Hootsuite
Pierga: For TNBC treated by neoadjuvant chemo, ctDNA and CTC '15 ref https://t.co/ZAZiYs32Ub #MDxE16
11:54am April 5th 2016 via Hootsuite
Pierga: follow-up after 43 mos: 3y OS 92% vs 56% comparing 0 CTCs vs detected. #MDxE16
11:48am April 5th 2016 via Hootsuite
Pierga: Goal to describe CTC counts, n=152, all IBC, detected >=1 CTC in 39%; observed strong drop during neoadjuvant Rx #MDxE16
11:45am April 5th 2016 via Hootsuite
Pierga: IBC represents 5% of breast cancers. BEVERLY 02 trial - used CellSearch, before adjuvant, after, before surgery, after #MDxE16
11:44am April 5th 2016 via Hootsuite
Pierga: Inflammatory breast ca - highly aggressive but rare form of locally advanced breast cancer (not immunological) 5y surv 40% #MDxE16
11:43am April 5th 2016 via Hootsuite
Pierga: Cp to GeparQuattro study looking at same Q: same incidence 22.2% CTC-pos patients #MDxE16
11:42am April 5th 2016 via Hootsuite
Pierga: 23% cases >=1 CTC, no correlation with pCR (!) during neoadjuvant chemo; PhII, N=118 #MDxE16
11:41am April 5th 2016 via Hootsuite
Jean-Yves Pierga (Univ Paris France): Circulating tumor cells (CTC) and pathological complete response (pCR) as prognostic factors #MDxE16
Allan: Examination of xenografts from cell lines via E- and N-cadherin, phenotypes are maintained in vivo #MDxE16
10:45am April 5th 2016 via Hootsuite
Allan: Also - undetectable CTCs (by CellSearch) increases with this ability to metastasize to distant location #MDxE16
Allan: Cell lines with 'increasingly mesenchymal' phenotype has an enhanced in-vivo capacity for metastasis to distant organs. #MDxE16
10:44am April 5th 2016 via Hootsuite
Allan: Subst. mouse anti-CD45, manual enrichment (due to blood vol differences), did negative selection #MDxE16
10:43am April 5th 2016 via Hootsuite
Allan: (But these are from cell line data - LNCaP 24-2B, PC-3, PC-3M) Orthotopic (prostate) inj into nude mice #MDxE16
10:38am April 5th 2016 via Hootsuite
Allan: Shows Lowes et al 16 (submitted) data w/ E-Cadherin data on EMT phenotype, cp to N-cadherin, vimentin, EpCAM #MDxE16
10:37am April 5th 2016 via Hootsuite
Allan: Recognizing EMT and CTC heterogeneity. CTCs less predictive as cannot be picked up by CellSearch. #MDxE16
10:36am April 5th 2016 via Hootsuite
Allan: '08 Prostate ca and CellSearch Kaplan Meier https://t.co/Mgqw46UJ9E 5 cells have clinical prognostic value #MDxE16
10:32am April 5th 2016 via Hootsuite
Allan: Working on the basic science; highlighting metastatic role of CTCs. Metastasis causes 90% of prostate ca deaths #MDxE16
10:28am April 5th 2016 via Hootsuite
Alison Allan (Western U Canada): Role of epithelial-to-mesenchyma transition (EMT) on CTC generation and metastasis in prostate ca #MDxE16
10:27am April 5th 2016 via Hootsuite
Q: Has it been used on a patient yet? Any add'l cell lines? Cerf: Only 1 pt so far, with prostate-cancer specific markers #MDxE16
10:19am April 5th 2016 via Hootsuite
Cerf: 3 prototypes for intravenous catheter tested in minipigs. Guides, strips, apertures, inside the 18G needle #MDxE16
10:15am April 5th 2016 via Hootsuite
Cerf: The goal - to have a microdevice to insert into a medical catheter; self-centering in the middle of the vein, easy to handle #MDxE16
10:12am April 5th 2016 via Hootsuite
Cerf: Onto whole blood capture - spike-in PC3 into blood from healthy donors (no fixation), 25K cells/mL, 10 min at 0.07m/s no clogs #MDxE16
10:11am April 5th 2016 via Hootsuite
Cerf: A minimal velocity change in pressure during capture - <100Pa upon capture. #MDxE16
10:09am April 5th 2016 via Hootsuite
Cerf: Spiked and fixed PC3 cell lines - shows SEM that morphology maintained post-capture. Impt of 3D capture vs 2D planes #MDxE16
10:08am April 5th 2016 via Hootsuite
Cerf: Focus on hole geometry; ideal thickness, PC3 prostate ca cell lines. 10um diameter holes, 6um thick membrane #MDxE16
10:07am April 5th 2016 via Hootsuite
Cerf: Velocity mimics in vivo conditions, 10 cm/s. 1mm2 PDMS channel. Characterized with confocal microscopy from bottom #MDxE16
10:06am April 5th 2016 via Hootsuite
Cerf: Can fabricate a post, with the device on top. Post 300um x 350um; cap about 150um on top. Flow through device - 1000 Pa #MDxE16
10:05am April 5th 2016 via Hootsuite
Cerf: Use tech from Nanoscribe, shows SEM of tubes with gridded holes on bottom of roof. Looks like a bullet-shaped hallow cap #MDxE16
10:04am April 5th 2016 via Hootsuite
Cerf: Direct laser writing technique - droplet of photosens resist, can create 3D nanostructures from nm to um scale, flex materials #MDxE16
10:03am April 5th 2016 via Hootsuite
Cerf: A grid at the bottom of device, 200-300um (compatible w/18G catheters) balance blood vol vs limited perturbation #MDxE16
10:02am April 5th 2016 via Hootsuite
Cerf: Concept is in vivo capture, not perturbing laminar flow from vascular system. Want to avoid microvortexes. #MDxE16
10:01am April 5th 2016 via Hootsuite
Cerf: In vitro may introduce bias by sampling; immunodetection may downregulate EpCAM expression with EMT #MDxE16
9:57am April 5th 2016 via Hootsuite
Cerf: About 50 technologies for CTCs - 90% are in-vitro platforms, only one in-vitro (GILUPI) with metal wires coated with EpCAM #MDxE16
Cerf: Also importance of CTC clusters not mentioned here yet. They set out to solve a few of these challenges. #MDxE16
9:56am April 5th 2016 via Hootsuite
Cerf: Little also known about location gradients of CTC concentration throghout vasculature #MDxE16
9:55am April 5th 2016 via Hootsuite
Cerf: LAAS-CNRS has 700 researchers. Today's focus on CTCs: dynamic release into the circulation not well char. Weeks vs hours? #MDxE16
Aline Cerf (CNRS U Cancer Toulouse / NanoBioSystems) 3D microdevice for the in vivo trapping of cancer-associated circulating cells #MDxE16
9:53am April 5th 2016 via Hootsuite
Lianidou: 'The first reported 'liquid biopsy' trial '12 https://t.co/scBmKkN3hr PhII study of early br ca relapse in response to Rx #MDxE16
9:46am April 5th 2016 via Hootsuite
Lianidou: Onto miRNA - cp FFPE to EpCAM+ CTCs data shown (however briefly) #MDxE16
9:44am April 5th 2016 via Hootsuite
Lianidou: HRM for ER+ br ca pts, detection in CTCs in non-responders to hormone Rx #MDxE16
9:42am April 5th 2016 via Hootsuite
Lianidou: Mutation analysis for PIK3CA, doing high-resolution melt (HRM) in metastatic br ca. Showed cp to FFPE primary tumors #MDxE16
9:41am April 5th 2016 via Hootsuite
Lianidou: Looking at ESR1 methylation in EpCAM+ CTCs. Pointed to her lab page https://t.co/nR4NyNqTmX #MDxE16
9:40am April 5th 2016 via Hootsuite
Lianidou: MSP: methylation-spec PCR, as a 3-plex, with a Luminex readout. 'Hard to develop but easy to apply' #MDxE16
9:39am April 5th 2016 via Hootsuite
Lianidou: EpCAM+ CTCs, CellSearch run in parallel. Looking at PD-L1 (see Chen's work) and AR-V7 alt splice variants. #MDxE16
9:38am April 5th 2016 via Hootsuite
Lianidou: (CellCollector method). After enrichment, showed list of some 25 genes seen in early prostate (n=62) and healthy (n=18) #MDxE16
9:34am April 5th 2016 via Hootsuite
Lianidou: Now focusing on early breast and prostate cancers. CTC-scan: mentioned by Pantel earlier, using GILUPI wires #MDxE16
9:32am April 5th 2016 via Hootsuite
Lianidou: BMC Cancer '11 https://t.co/WeWTfmMNE8 quantitated CK-19, add'l 5 genes #MDxE16
9:31am April 5th 2016 via Hootsuite
Lianidou: Showed '03 and '06 results for CK-19 mRNA+ cells in br ca pts. Shown in '09 JCO ref https://t.co/vK5blavxqC #MDxE16
9:29am April 5th 2016 via Hootsuite
Lianidou: Approach is comprehensive; EpCAM+ w/paired plasma, total RNA, DNA, bisulfite for MSP assay. #MDxE16
9:28am April 5th 2016 via Hootsuite
